

Ms. Maria A. Figuerola Santos
DG Health and Consumers
European Commission
Office 10/130
B-1049 Brussels
Belgium

17 December 2012

Re: Hospital Exemption ATMPs

Dear Ms. Figuerola Santos,

The Alliance for Advanced Therapies (AAT), EuropaBio and European Biopharmaceutical Enterprises (EBE) are pleased with the European Commission's continued focus on the development of advanced therapies in Europe.

Our Associations are committed to improving the advanced therapies climate in Europe in order to bring safe and innovative treatments to patients as early as possible.

We have contacted you earlier this year about a number of possible improvements to the European advanced therapies climate, including a proper and harmonized implementation of the Hospital Exemption in the Member States.

We would appreciate the opportunity to discuss with you the improvements mentioned above and our plans for coordinated follow-up activities. We therefore kindly request a meeting with you.

Please do not hesitate to contact us with any questions that you might have.

We look forward to your response.

Kind regards,

Alliance for
Advanced Therapies




Rob T.A. Janssen
Secretary-General

EuropaBio



Miriam Gargesi
Healthcare Director

European Biopharmaceutical
Enterprises



Titta Rosvall-Puplett
Executive Director

Alliance for Advanced Therapies

Palissanderhout 2
2719 KW Zoetermeer
The Netherlands

Tel.: +31 79 362 29 50
Fax.: +31 79 360 03 06
Mob.: +31 6 54 70 88 65

E-mail: info@allianceat.org
Web: www.allianceat.org

EuropaBio

Avenue de l'Armée 6
1040 Brussels
Belgium

General phone number: +32 2 739 11 74
Fax number: +32 2 735 49 60

E-mail: d.cassidy@europabio.org

European Biopharmaceutical Enterprises

Rue du Trône 108
Leopold Plaza Building
B-1050 Brussels
Belgium

T: +32 2 626 25 55
F: +32 2 626 25 66

E-mail: info@ebe-biopharma.org
Web: www.ebe-biopharma.org